The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs. “In this scheme, CanaRx facilitates foreign physicians rewriting the employee’s U.S. prescription, and then supplies the employee with unapproved versions of FDA-approved drugs purportedly sourced from Canada, the United Kingdom or Australia that are represented to have undergone review from those countries’ drug regulatory systems,” FDA said. “This is particularly troublesome, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s ‘insurance’ plan and may not question their legitimacy.” The letter lists more than 150 websites affiliated with the company. FDA said health care providers and consumers should report any adverse events related to drugs provided by CanaRx to its MedWatch program.

Related News Articles

Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
The Department of Health and Human Services aims to release proposed rules amending the physician self-referral (Stark law) regulations and safe-harbors under…
Headline
The Department of Health and Human Services Office for Civil Rights today published in the Federal Register its final rule concerning federal health care-…
Blog
Last week, researchers at RAND released a study that made broad claims about the prices that private insurers pay hospitals. The RAND authors relied on…
Headline
Sens. Bill Cassidy, R-La., Michael Bennet, D-Colo., Todd Young, R-Ind., Maggie Hassan, D-N.H., Lisa Murkowski, R-Alaska, and Tom Carper, D-Del., today…